[This is an outright asset purchase (not a license or partnership) for $170M in up-front cash and a potential $20M in milestones. The compound in question is for pain and is only in phase-1, so ABT must really like the MoA to be paying this much.]
›Anti-NGF Compound Adds to Company's Early-Stage Pain Care Pipeline
9:00 am EST, Thursday November 12, 2009
ABBOTT PARK, Ill., Nov. 12 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain. NGF is released at sites of tissue damage and inflammation, and plays a significant role in the transmission of pain signals by the central nervous system.
"The goal for treatment of chronic pain continues to be potent, long-lasting analgesia that is tolerable for patients without the potential for dependence and abuse," said John Leonard, M.D., senior vice president, global research and development, Abbott. "NGF blockers have demonstrated the potential to address all of these needs, making them a promising treatment for chronic pain patients."
Pain is the number one reason people go to see a doctor. There are an estimated 72 million diagnosed chronic pain patients in the U.S. and EU, and up to 30 percent of chronic pain patients get inadequate relief. Current treatments consist of NSAIDs, selective Cox-2 inhibitors, opioids and other analgesics that are dosed daily and have various tolerability and safety issues, including the potential for abuse and addiction.
PG110 is currently being studied in a Phase I clinical trial in patients with osteoarthritis. If the Phase I trial is successful, Abbott anticipates evaluating the compound in a number of other pain states, including chronic lower back pain, cancer pain and diabetic neuropathic pain.
This new NGF inhibitor complements Abbott's robust early-stage pipeline of candidates in development for chronic pain, which spans multiple mechanisms, including vanilloid cellular receptors (TRPV1), cannabinoid receptors (CB2), Histamine H3 receptors and preclinical work on a number of promising ion channel targets.
The agreement includes an upfront payment of $170 million plus additional milestone payments, for a total of up to $190 million. This transaction is subject to customary closing conditions and regulatory approvals and is expected to close in the fourth quarter of 2009. Abbott would expect to incur one-time specified items upon the closing of the acquisition, primarily related to in-process research and development. This transaction does not impact Abbott's previously issued ongoing earnings-per-share guidance for 2009.‹
[Updates: Niaspan bests Zetia in head-to-head study; three-year data on bioabsorbable stent; what’s up with MRK’s Cordaptive; ABT acquires anti-NGF mAb for $170M.]
Drug business (general) #msg-42490961 Humira continues on monster pace #msg-39417561Size and segments of US market for RA #msg-26156472 FDA approves Humira for plaque psoriasis #msg-29106939 ABT showcases ADHD portfolio #msg-38562229 FDA requests new Flutiform trial
News 
Market Data 
Discover 
AI
